Your browser doesn't support javascript.
loading
Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer.
Strusi, Alessandro; Pinterpe, Giada; Ciccarese, Chiara; Pedone, Romina Rose; Sarcina, Michele; Sardaro, Valeria; Belletto, Rachele; Totaro, Angelo; Racioppi, Marco; Berardi, Rossana; Tortora, Giampaolo; Iacovelli, Roberto.
Affiliation
  • Strusi A; Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Pinterpe G; Clinica Oncologica e Centro Regionale di Genetica Oncologica, AOU delle Marche, Ancona, Italy.
  • Ciccarese C; Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Pedone RR; Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Sarcina M; Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Sardaro V; Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Belletto R; Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Totaro A; Urology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Racioppi M; Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Berardi R; Urology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Tortora G; Clinica Oncologica e Centro Regionale di Genetica Oncologica, AOU delle Marche, Ancona, Italy.
  • Iacovelli R; Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
Expert Rev Anticancer Ther ; : 1-4, 2024 Jun 27.
Article in En | MEDLINE | ID: mdl-38932631
ABSTRACT
The 2024 ASCO Genitourinary Cancer Symposium, this year celebrating the 20th anniversary, delved into key advancements in urothelial carcinoma (UC) and prostate cancer (PC). For UC, insights emerged from adjuvant pembrolizumab for muscle-invasive urothelial carcinoma, and from the efficacy of the EV-302 study of enfortumab vedotin +pembrolizumab in the metastatic setting. In PC, adjuvant therapy with high-dose radiotherapy schedules plus long-t erm ADT was explored. In metastatic castration-resistant PC, highlights included a novel combo (cabozantinib+atezolizumab) for poor prognosis patients; confirmed benefits of ARSI+PARPi in BRCA-mutated patients; and safety considerations for ARSI treatments. The symposium continued its role as an indispensable platform for shaping specialized oncological care.
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Expert Rev Anticancer Ther Journal subject: NEOPLASIAS / TERAPEUTICA Year: 2024 Document type: Article Affiliation country: Italia
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Expert Rev Anticancer Ther Journal subject: NEOPLASIAS / TERAPEUTICA Year: 2024 Document type: Article Affiliation country: Italia